BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23826558)

  • 1. Is prostate-specific antigen effective for population screening of prostate cancer? A systematic review.
    Lee YJ; Park JE; Jeon BR; Lee SM; Kim SY; Lee YK
    Ann Lab Med; 2013 Jul; 33(4):233-41. PubMed ID: 23826558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.
    Ilic D; Djulbegovic M; Jung JH; Hwang EC; Zhou Q; Cleves A; Agoritsas T; Dahm P
    BMJ; 2018 Sep; 362():k3519. PubMed ID: 30185521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
    Hayes JH; Barry MJ
    JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for prostate cancer: an updated Cochrane systematic review.
    Ilic D; O'Connor D; Green S; Wilt TJ
    BJU Int; 2011 Mar; 107(6):882-91. PubMed ID: 21392207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer.
    Ilic D; O'Connor D; Green S; Wilt T
    Cochrane Database Syst Rev; 2006 Jul; (3):CD004720. PubMed ID: 16856057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update.
    Bennett A; Beck A; Shaver N; Grad R; LeBlanc A; Limburg H; Gray C; Abou-Setta A; Klarenbach S; Persaud N; Thériault G; Thombs BD; Todd KJ; Bell N; Dahm P; Loblaw A; Del Giudice L; Yao X; Skidmore B; Rolland-Harris E; Brouwers M; Little J; Moher D
    Syst Rev; 2022 Oct; 11(1):230. PubMed ID: 36289518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lycopene for the prevention of prostate cancer.
    Ilic D; Forbes KM; Hassed C
    Cochrane Database Syst Rev; 2011 Nov; 2011(11):CD008007. PubMed ID: 22071840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.
    Rove KO; Crawford ED
    World J Urol; 2012 Apr; 30(2):137-42. PubMed ID: 22116599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Japanese guideline for prostate cancer screening.
    Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
    Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients.
    Merriel SWD; Pocock L; Gilbert E; Creavin S; Walter FM; Spencer A; Hamilton W
    BMC Med; 2022 Feb; 20(1):54. PubMed ID: 35125113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
    Paschen U; Sturtz S; Fleer D; Lampert U; Skoetz N; Dahm P
    BJU Int; 2022 Mar; 129(3):280-289. PubMed ID: 33961337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
    Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
    Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.